"As a result, GSK now expects to increase its annual production capacity of Relenza to 190 million treatment courses by the end of 2009. This represents a threefold increase to GSK's previous maximum capacity of 60 million treatment courses," the company said in a statement.
The production will be 190 million by the end of 2009, so why does the idiot say Biota will no recieve money until 2010.
The forward sales of 190m to governments are spoken for and surely progressive payments will follow the Relenza deliveries throughout 2009 and early 2010.
What a wanker.
BTA Price at posting:
$1.77 Sentiment: Buy Disclosure: Held
